During the past decade, The Second Hospital of Jilin University conducted 86 clinical trials. In the 10-year time frame, 86 clinical trials started and 11 clinical trials were completed, i.e. on average, 12.8% percent of trials that started reached the finish line to date. In the past 5 years, 47 clinical trials started and 9 clinical trials were completed. i.e. 19.1% of trials that started reached the finish line.

Out of the total clinical trials conducted in "The Second Hospital of Jilin University" #1 sponsor was "Chia Tai Tianqing Pharmaceutical Group Co., Ltd." with 5 trials, followed by "Eli Lilly and Company" with 5 trials sponsored, "Second Hospital of Jilin University" with 5 trials sponsored, "Chengdu Kanghong Biotech Co., Ltd." with 4 trials sponsored and "Harbin Medical University" with 4 trials sponsored. Other sponsors include 72 different institutions and companies that sponsored additional 60 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "The Second Hospital of Jilin University" #1 collaborator was "Second Hospital of Jilin University" with 8 trials as a collaborator, "First Affiliated Hospital Xi'an Jiaotong University" with 4 trials as a collaborator, "First Affiliated Hospital of Xinjiang Medical University" with 3 trials as a collaborator, "Guangdong Provincial People's Hospital" with 3 trials as a collaborator and "Shandong Provincial Hospital" with 3 trials as a collaborator. Other collaborators include 252 different institutions and companies that were collaborators in the rest 236 trials.

According to Clinical.Site data, the most researched conditions in "The Second Hospital of Jilin University" are "Coronary Artery Disease" (10 trials), "Macular Edema" (5 trials), "Breast Cancer" (4 trials), "Acute Myocardial Infarction" (3 trials) and "Breast Neoplasms" (3 trials). Many other conditions were trialed in "The Second Hospital of Jilin University" in a lesser frequency.

Most popular intervention types in "The Second Hospital of Jilin University" are "Drug" (72 trials), "Device" (10 trials), "Procedure" (9 trials), "Other" (5 trials) and "Diagnostic Test" (3 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (19 trials), "placebo" (4 trials), "Aflibercept" (3 trials), "Faricimab" (3 trials) and "Sham Procedure" (3 trials). Other intervention names were less common.

The vast majority of trials in "The Second Hospital of Jilin University" are 96 trials for "All" genders and 4 trials for "Female" genders.

Currently, there are NaN active trials in "The Second Hospital of Jilin University". 3 are not yet recruiting, 20 are recruiting, 10 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 43 completed trials in The Second Hospital of Jilin University, undefined suspended trials, and 5 terminated clinical trials to date.

Out of the total trials that were conducted in The Second Hospital of Jilin University, 2 "Phase 1" clinical trials were conducted, 13 "Phase 2" clinical trials and 42 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 12 trials, and there were also 18 trials that are defined as “Not Applicable".